Back to top

oncology-screening: Archive

Zacks Equity Research

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.

BMYPositive Net Change PFEPositive Net Change REPLNegative Net Change ALLONegative Net Change